News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement

Charlene Prounis

Advertisement

Articles by Charlene Prounis

Marketing to Professionals: Doctor-Patient Communication

ByCharlene Prounis
September 1st 2005

Instead of leaving the doctor's office well informed, the patient often leaves without enough comprehensible information to comply with the prescribed treatment.

Advertisement

Latest Updated Articles

  • Marketing to Professionals: Doctor-Patient Communication
    Marketing to Professionals: Doctor-Patient Communication

    Published: September 1st 2005 | Updated:



Advertisement
Advertisement

Trending on PharmExec

1

WHO Finalizes United States’ Withdrawal from Organization: Report

2

JP Morgan 2026 Wrap Up: Pharma Leaders Speak About the Conference and the State of the Industry

3

Novavax Enters $530 Million License Agreement with Pfizer for Vaccine Development

4

Janux Therapeutics Enters $850 Million Collaboration and Exclusive License Agreement with Bristol Myers Squibb to Develop Tumor-Activated Therapeutics

5

What is Daiichi Sankyo’s Post JP Morgan Strategy?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us